Telix Pharmaceuticals Expands Through $3.3 Billion Radiopharmaceutical Deal
Australian radiopharmaceutical company Telix Pharmaceuticals is set to expand its global presence through a major deal with German isotope specialist ITM Isotope Technologies Munich, in a transaction valued at up to $3.3 billion. The ASX-listed company has agreed to acquire ITM in a deal involving an upfront payment of at least US$1.65 billion, or approximately $2.3 billion, in Telix shares. ITM is a privately owned company specialising in the production and supply of medical radioisotopes and has a distribution network reaching more than 65 countries. Telix chief executive and managing director Dr Christian Behrenbruch described the agreement as a significant development for both companies. The transaction is expected to combine Telix's expertise in radiopharmaceutical medicines with ITM's capabilities in isotope production and supply. Although the companies have referred to the arrangement as a merger, Telix shareholders are expected to hold approximately 76.3 per cent of th...